Epclusa

FDA Approves Gilead’s Epclusa for Children with Hepatitis C
FDA Approves Gilead’s Epclusa for Children with Hepatitis C
BioSpace
Epclusa
hepatitis C
Gilead Sciences
FDA
pediatric
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Fierce Pharma
Gilead Sciences
hepatitis C
Epclusa
drug ads
television ads
Flag link:
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
CP Wire
Gilead Sciences
generics
Epclusa
Harvoni
hepatitis C
Asegua Therapeutics
Flag link:
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead
Epclusa
Harvoni
Flag link:
5 Drugs That Are Critical for Gilead Sciences' Future
5 Drugs That Are Critical for Gilead Sciences' Future
Motley Fool
Gilead Sciences
Biktarvy
Yescarta
selonsertib
filgotinib
Epclusa
Flag link:
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
The 1 Thing Missing From Gilead Sciences' 2018 Priority List
Motley Fool
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
Epclusa
Flag link:
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
Gilead's HCV NDA Means Nothing
Gilead's HCV NDA Means Nothing
Seeking Alpha
Gilead Sciences
hepatitis C
SOF/VEL/VOX
Epclusa
AbbVie
Flag link:
After The Deluge, Hep C Players Look For Opportunity
After The Deluge, Hep C Players Look For Opportunity
Seeking Alpha
hepatitis C
Gilead Sciences
AbbVie
Epclusa
glecaprevir/pibrentasvir
sofosbuvir/velpatasvir
Flag link:
AbbVie's pan-genotypic hep C prospect shines in trials, putting the heat on rival Gilead
AbbVie's pan-genotypic hep C prospect shines in trials, putting the heat on rival Gilead
Fierce Pharma
AbbVie
hepatitis C
Gilead Sciences
Epclusa
Flag link:
What’s New with Gilead Sciences?
What’s New with Gilead Sciences?
Market Realist
Gilead Sciences
GS-5745
Truvada
Odefsey
Epclusa
Flag link:
Gilead Sciences, Inc. HCV Script Data: Epclusa May Lighten The Blow
Gilead Sciences, Inc. HCV Script Data: Epclusa May Lighten The Blow
Bidness, ETC
Gilead Sciences
hepatitis C
Epclusa
prescription data
Flag link:
Gilead secures European approval for new hepatitis C drug
Gilead secures European approval for new hepatitis C drug
BioPharma Dive
Gilead Sciences
Europe
hepatitis C
Epclusa
Flag link:
3 Potential Stock-Moving Drug Events In The Second Half Of 2016
3 Potential Stock-Moving Drug Events In The Second Half Of 2016
Investors.com
Eli Lilly
solanezumab
Alzheimer's disease
Gilead Sciences
hepatitis C
Sovaldi
Harvoni
Epclusa
Sanofi
Regeneron
Praluent
Flag link:
Why Gilead's new hepatitis C drug is a game changer — price and all
Why Gilead's new hepatitis C drug is a game changer — price and all
Bizjournals.com
Gilead Sciences
hepatitis C
drug pricing
Epclusa
Flag link: